Fig. 3
From: Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
BKM-120 and olaparib in combination effect in PTEN wild-type and mutated endometrial cancer cells. PTEN mutated a and wild-type b cancer cells were treated with increasing doses of BKM-120 in the presence of low doses of 0.1 μM or 0.5 μM olaparib for 7 days and their effect on cell proliferation was determined using the clonogenic assay. c The combination index was calculated where CI < 1 indicates synergy between the two drugs. Data represents the average of three independent experiments. Data not shown for 0.5 μM olaparib.*p value <0.05